Clinical Trial: Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802626) titled 'Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing' on Aug. 28.

Brief Summary: The purpose of this research is to see if adding the investigational targeted drug capivasertib to standard endocrine therapy (hormone-blocking treatment) combined with a medicine that slows cancer cell growth can improve response to treatment for patients with metastatic breast cancer that's hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: HR Positive/HER-2 Negative Breast Can...